- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05406167
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System (PREMIER)
Prospective Data Registry and Quality of Life Assessment of PatientsUndergoing Radiotherapy With the RefleXion Medical Radiotherapy System (PREMIER Registry)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multi-center prospective registry designed to assess the efficacy of IMRT and SBRT delivered via the RMRS. The study will seek to enroll approximately 500 patients initially and then remain open to further patients beyond at the discretion of the study sponsor and participating institutions. The number of IMRTandSBRT patients expected to enroll for the initial period is as follows:
- N = 250 IMRT
- N = 250 SBRT
Patients diagnosed with local, locoregionally advanced, or metastatic malignancies will be treated with IMRT or SBRT using the RMRS, with total dose, fractionation, and concurrent systemic therapy delivered according to the direction of the radiation oncology care team. The target population is patients for whom standard radiotherapy is prescribed using IMRT or SBRT. Data will be stratified by common radiotherapy divisions as follows:
- Central Nervous System (Brain, spinal cord, and vertebral column)
- Head and Neck
- Thoracic
- Gastrointestinal
- Gynecologic
- Genitourinary
- Lymphoma
- Melanoma/Sarcoma/Extremity
- Non-Spine Bone and Other An additional substratum within each anatomic division will specify whether the treatment intent is for definitive treatment of the primary tumor (for early-stage or locally advanced disease), a definitive oligo/polymetastatic therapy, or a palliative therapy. Patients will be routinely assessed during their radiation course and thereafter for toxicity burden and HRQOL using the CTCAE v5, EORTC, and EuroQOL surveys. Patients will be assessed for 2years following their therapy. Other long-term follow-ups will capture data including routine laboratory evaluation, quality of life questionnaires, performance status, routine radiographic assessments, physical exams, etc.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Debradenise Brooks
- Phone Number: 6504828435
- Email: dbrooks@reflexion.com
Study Contact Backup
- Name: Didem Aksoy
- Email: daksoy@reflexion.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
Contact:
- Joan Marcia
- Email: jmarcia@coh.org
-
Contact:
- Diamond Ward
- Email: diward@coh.org
-
-
Texas
-
Dallas, Texas, United States, 75235
- Recruiting
- UT Southwestern
-
Principal Investigator:
- Tu Dan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Able to comprehend and willing to sign an informed consent form (ICF).
- Diagnosis of local, loco-regionally advanced, or metastatic malignancy for whom radiotherapy is indicated
- Radiotherapy to be delivered on the RMRS X1 with IMRT or SBRT technique.
- Absence of concurrent illness that deems radiotherapy a contraindication which will be determined by the treating radiation oncologist.
- Female and male patients of child-bearing potential willing to take appropriate precautions to avoid pregnancy while being treated. Permitted methods in preventing pregnancy should be communicated to the patient and their understanding confirmed by the treating Physician.
Exclusion Criteria:
- Pregnant or expecting to conceive during the study.
- Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with study requirements and follow-up visits.
- Inability to maintain immobilization, supine position for planning and treatments.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Stereotactic Body Radiotherapy [SBRT]
Patients treated with Reflexion X1 with SBRT as the standard of care
|
Observation Registry for Medical Device
Other Names:
|
Intensity -Modulated Radiation Therapy [IMRT]
Patients treated with Reflexion X1 with IMRT as the standard of care
|
Observation Registry for Medical Device
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health Related Quality of Life (HRQOL) scores
Time Frame: 30 Days
|
Evaluate patient-reported quality of life after IMRT or SBRT treatment delivered by the RefleXion system by assessing EORTC QLQ-C30. The EORTC questionnaire has a scoring of 0 to 100 and is disease-specific. 0 is none/minimal symptoms and normal/good functional ability. 100 is increased/severe symptoms and decrease/poor functional ability. |
30 Days
|
Health Related Quality of Life (HRQOL) scores
Time Frame: 90 Days
|
Evaluate patient-reported quality of life after IMRT or SBRT treatment delivered by the RefleXion system by assessing EORTC QLQ-C30. The EORTC questionnaire has a scoring of 0 to 100 and is disease-specific. 0 is none/minimal symptoms and normal/good functional ability. 100 is increased/severe symptoms and decrease/poor functional ability. |
90 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long Term Health-Related Quality of Life-EORTC
Time Frame: 6 months, 9 months, 12 months, 18 months, and 24 months
|
Long-term Health-Related Quality of Life (HRQOL) scores, including the EORTC QLQ-C30 at 6 months, 9 months, 12 months, 18 months, and 24 months. The EORTC questionnaire has a scoring of 0 to 100 and is disease-specific. 0 is none/minimal symptoms and normal/good functional ability. 100 is increased/severe symptoms and decrease/poor functional ability. |
6 months, 9 months, 12 months, 18 months, and 24 months
|
Long Term Health Related Quality of Life-EuroQol
Time Frame: 6 months, 9 months, 12 months, 18 months, and 24 months
|
The EuroQOL-5D-FL (EQ-5D) will be used in parallel with the Health-Related Quality of Life (HRQOL) surveys to measure quality-adjusted life years. The EQ-5D comprises five questions on mobility, self-care, pain, usual activities, and psychological status with three possible answers for each item (1=no problem, 2=moderate problem, 3=severe problem. A summary index with a maximum score of 1 can be derived from these five dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state, by contrast with the scores of individual questions, where higher scores indicate more severe or frequent problems. |
6 months, 9 months, 12 months, 18 months, and 24 months
|
Acute toxicities related to Radiotherapy treatment
Time Frame: Up to 90 days
|
Proportion of patients with acute treatment toxicity for the anatomic site undergoing treatment
|
Up to 90 days
|
Disease Status [progression-free survival]
Time Frame: Through Study Completion, average of 2 years
|
Evaluate progression-free survival after intensity-modulated radiotherapy or stereotactic body radiotherapy for the cancers above.
For prostate cancer cohort, biochemical progression-free survival will also be measured.
|
Through Study Completion, average of 2 years
|
Disease Status [local recurrence]
Time Frame: Through Study Completion, average of 2 years
|
Evaluate local control after intensity-modulated radiotherapy or stereotactic body radiotherapy for the cancers above.
|
Through Study Completion, average of 2 years
|
Disease Status [regional recurrence]
Time Frame: Through Study Completion, average of 2 years
|
Evaluate regional control after intensity-modulated radiotherapy or stereotactic body radiotherapy for the cancers above.
|
Through Study Completion, average of 2 years
|
Disease Status [distant recurrence]
Time Frame: Through Study Completion, average of 2 years
|
Evaluate distant control after intensity-modulated radiotherapy or stereotactic body radiotherapy for the cancers above.
|
Through Study Completion, average of 2 years
|
Disease Status [overall survival]
Time Frame: Through Study Completion, average of 2 years
|
Evaluate overall survival after intensity modulated radiotherapy or stereotactic body radiotherapy for the cancers above.
|
Through Study Completion, average of 2 years
|
Intervention and Episodic costs
Time Frame: Up to 6 months
|
Analyze resource utilization associated with the RefleXion system for the tumors above including the acute costs of intervention & 6-month episodic costs.
|
Up to 6 months
|
Long-term toxicities related to Radiotherapy
Time Frame: After 90 days through study completion
|
Analyze long term treatment toxicity for the anatomic site undergoing treatment
|
After 90 days through study completion
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sean Shirvani, MD, RefleXion Medical
- Study Director: Karine Feghali, MD, RefleXion Medical
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 985-00003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Registry - Observational
-
St. Louis UniversityActive, not recruitingVertebral Artery StenosisUnited States
-
Central Hospital, Nancy, FranceInstitut National de la Santé Et de la Recherche Médicale, France; University...Recruiting
-
IVAN J NUÑEZ GILCompleted
-
University of BolognaAssociazione Per La Ricerca Cardiologica (Roma)Recruiting
-
Henry Ford Health SystemCompletedAcute Coronary SyndromeUnited States
-
Medical University of BialystokRecruiting
-
The Diabetes Association of the Republic of China...Recruiting
-
Tufts Medical CenterNational Kidney FoundationActive, not recruitingChronic Kidney Disease | Dialysis | Kidney TransplantUnited States
-
University of Cape TownCompletedAcute Coronary Syndrome | Unstable Angina | ST Elevated Myocardial Infarction | Non ST Elevation Myocardial InfarctionSouth Africa
-
MedtronicRecruitingSurgical Procedures, Operative | Minimally Invasive Surgical ProceduresUnited States